Analystreport

Theravance Biopharma Inc (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $55.00 price target on the stock.

Theravance Biopharma, Inc. - Ordinary Shares  (TBPH) 
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.theravance.com/investor-relations